Pipeline

Rain has built a pipeline of targeted oncology therapies. For more information on each of our programs, please visit our Science page.

Program Overview

RainPipeline
Program Indication / Strategy Phase
RAIN-32
(DS-3032) MDM2
WD / DD Liposarcoma Phase 2
MDM2 Basket Study Phase 1a
AML: FLT3-ITD / Quizartinib Phase 1a
Tarloxotinib
Pan-HER
NSCLC: HER2 Ex20 Phase 2
Basket: NRG1 / HER Fusions1 Phase 2
RAD52 Research Program PARP-relapsed. HRD+Tumors Preclinical
BRCA-deficient tumors Preclinical

1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions